| Colchicine myopathy and neuromyopathy: two cases with different characteristics. | |
| | |
MedLine Citation:
|
PMID: 20661070 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Colchicine, a long established anti-inflammatory agent now used in several rheumatologic conditions, acts by inhibiting microtubular polymerization, as it binds equimolarly to tubulin molecules. Cytoskeletal microtubules are crucial in processes of cell viability, such as mitosis and intracellular vesicle motility.Gastrointestinal side effects are quite common and often minor in nature or duration, whereas neuromuscular toxicity is rare. We report 2 cases of colchicine myopathy in the context of very different clinical settings. |
| | |
Authors:
|
Luca Cantarini; Nila Volpi; Mauro Galeazzi; Teresa Giani; Francesca Fanti; Orso Maria Lucherini; Margherita Aglianò; Carlo Alessandrini; Fabio Giannini; Stefania Magi; Giuseppe Greco; Cosima Tatiana Baldari; Rolando Cimaz |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases Volume: 16 ISSN: 1536-7355 ISO Abbreviation: J Clin Rheumatol Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-27 Completed Date: 2010-12-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9518034 Medline TA: J Clin Rheumatol Country: United States |
Other Details:
|
Languages: eng Pagination: 229-32 Citation Subset: IM |
Affiliation:
|
Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Unit of Rheumatology, Policlinico Le Scotte, University of Siena, Siena, Italy. cantariniluca@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Arthritis, Gouty / drug therapy Colchicine / adverse effects*, metabolism, therapeutic use Cytochrome P-450 CYP3A / metabolism Familial Mediterranean Fever / drug therapy Female Humans Male Middle Aged Muscle Weakness / chemically induced, diagnosis Muscular Diseases / chemically induced*, diagnosis P-Glycoprotein / metabolism Tubulin Modulators / adverse effects*, metabolism, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/P-Glycoprotein; 0/Tubulin Modulators; 64-86-8/Colchicine; EC 1.14.13.67/CYP3A4 protein, human; EC 1.14.14.1/Cytochrome P-450 CYP3A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Two cases of recurrent stroke in treated giant cell arteritis: diagnostic and therapeutic dilemmas.
Next Document: Polymorphisms in the caspase genes and the risk of lung cancer.